Research programme: antibody cancer therapeutics - I-Mab/Immorna
Latest Information Update: 24 Nov 2022
At a glance
- Originator Immorna
- Developer I-MAB Biopharma; Immorna
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Liver cancer